US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Follicum reports revised top-line results from the Phase IIa study of FOL-005 for the treatment of hair loss (alopecia)

Follicum AB (publ ) today reports revised top line data from a Phase IIa study of the tissue repairing peptide FOL-005 for the treatment of hair loss (alopecia). The revised data are based on an independent review that was conducted due to errors detected in the performance analysis presented by the Company on May 6, 2021. The revised results show no significant differences compared to what was previously reported and the Company stands by the decision to discontinue development of the product for the treatment of hair loss. However, Follicum will continue to explore opportunities to further

BioStock: Hopeful stock surge in Follicum after suspected analysis error in hair loss project

Many people’s hopes for Follicum’s hair loss project were dashed in May when the company presented top-line results demonstrating that the drug candidate FOL-005 did not show any significant effect compared to placebo. Hopes for the project were rekindled on Wednesday when the company announced possible inaccuracies in the analysis of the results, news that caused the stock to soar. An external review of the study results is now underway and the company’s CEO Kim Arvid Nielsen does not want to make any assumptions until it is completed.Read the full article at biostock.se: https://www.

BioStock: Follicum’s new CEO on the next steps in the company’s development journey

Kim Arvid Nielsen recently took over as CEO of the research company Follicum, at a time when the company stands at an important junction for its further development work. BioStock has spoken to the newly appointed CEO to get his view of the company and to learn more about which activities will be most important in the near future.Read the full article at biostock.se: https://www.biostock.se/en/follicums-new-ceo-on-the-next-steps-in-the-companys-development-journey/This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se

Follicum appoints Jonas Edelswärd as new CFO

Follicum AB today announces that Jonas Edelswärd has been appointed as new CFO. He succeeds Fredrik Werner, who has decided to leave his position after 2 years in the company. Jonas Edelswärd will take up his position on 10 May.Jonas Edelswärd, with a MSc in Economics has more than 20 years of experience from various positions in high-tech startups. He has also worked with more mature companies when he acted as CEO of the investment company AB Axel Granlund in Malmö. Jonas Edelswärd is chairman of the board of Zaplox AB, board member of Galenica AB, Pragati AB and Humanus Utbildning Syd AB

Follicum reports top-line results from Phase IIa study of FOL-005 for treatment of hair loss (alopecia)

Follicum AB (publ) today reports top-line data from a Phase IIa study of the tissue repairing peptide FOL-005 for treatment of hair loss  (alopecia).  The study examined safety and therapeutic efficacy after daily treatment with the product for four  months. The results confirmed that the treatment was safe and only a few mild side effects were reported. Hair growth increased significantly in the group of patients receiving FOL-005 treatment at the highest dose studied, but no significantly better efficacy compared to the placebo group could be demonstrated. Follicum will  conduct further

BioStock: New data strengthens Follicum’s diabetes project

Follicum, a company that develops tissue repair peptides, has advanced further in its preclinical work with developing a drug candidate for the treatment of diabetes. Through extensive and advanced experimental work, the company believes that the peptides bind to a specific receptor in the membranes of cells that are considered to play an important role in the protection and repair of organ tissue. BioStock has contacted Follicum’s CEO Jan Alenfall to learn more about what this means for the project.Read the full article at biostock.se:https://www.biostock.se/en/new-data-strengthens-

Follicum appoints new CEO and establishes new role as Chief Scientific Officer

Follicum AB announces today that the company has recruited Dr. Kim Arvid Nielsen as new CEO, taking office on April 6, 2021. He has extensive experience in business development, investor relations and drug development from leading positions in both small and large pharmaceutical companies. At the same time, Follicum is establishing a new position as Chief Scientific Officer. The changes are implemented to strengthen the company's organization to keep in step with the progress made in its pharmaceutical projects.Follicum has recently made continued progress in its pharmaceutical projects

New preclincial study confirms mechanism of action of Follicum’s novel tissue repair peptides

Follicum AB today announces that significant progress has been made in the company's development of new drug treatments for diabetes and other diseases. Within the framework of a preclinical research project, the interaction between one of Follicum's tissue-repairing peptide families and a specific receptor has been characterized in detail. This will help accelerate continued optimization work aimed at advancing the company's preclinical projects to the clinical phase and increases their attractiveness among potential commercial partners. Follicum's most advanced drug candidate, FOL-005, is

BioStock: All patients have completed treatment in Follicum’s phase IIa trial

For Follicum, one of this year’s main events will be the topline result from the ongoing phase IIa study with the company’s candidate FOL-005 for treatment of hair loss. The company announced on Thursday that all patients in the study have undergone treatment and that results are expected in the spring. BioStock talked to Follicum’s CEO Jan Alenfall to find out more.Read the full article at biostock.se: https://www.biostock.se/en/all-patients-have-completed-treatment-in-follicums-phase-iia-trial/This is a press release from BioStock - Connecting Innovation & Capital.https://www.

Follicum AB reports that all patients have completed treatment with FOL-005 in the Phase II study against hair loss

Follicum AB today announced that all patients in the ongoing Phase IIa study with FOL-005 for the treatment of hair loss have completed treatment and made their final visits to the clinic. The study examines the safety and treatment effect of different doses of the drug candidate FOL-005  in just over 200 male patients. Top line results are expected to be presented during spring 2021.The ongoing double-blind and placebo-controlled Phase IIa study examines the safety and efficacy of FOL-005 in a new, cream-like formulation. The patients themselves have applied one of three different

Follicum receives European patent for the company's peptides for developing first in class diabetes treatments

Follicum AB today announces that the European Patent Office (EPO) has approved the patent EP 3 618 845  B1, which refers to the  company's novel peptides that are being developed to treat diabetes. The approval follows the previous provisional approval by the EPO announced on March 20, 2020.The approval by the EPO of patent No. EP 3,618,845 B1 provides protection for the company's peptides and their use to treat diabetes in Europe until 2038. Similar patents have previously been approved in the United States. In addition, Follicum has a corresponding patent application under review by

BioStock: Follicum takes a step closer to phase III entering 2021

A productive 2020 for Follicum is capped off by the completion of patient recruitment for its phase II hair growth study for determining the best dose and treatment duration of candidate FOL-005. BioStock spoke with Follicum’s CEO Jan Alenfall to get his impressions on the company’s highlights for 2020 and what to expect in 2021Read the full interview with Follicum's CEO Jan Alenfall at biostock.se: https://www.biostock.se/en/follicum-takes-a-step-closer-to-phase-iii-entering-2021/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Follicum’s CEO comments on directed share issue of SEK 37 million

Last week, biotech company Follicum announced a directed share issue of SEK 36.6 million to a number of selected investors. The funds will be used to bring the ongoing phase II trial in hair loss across the finish line and advance the preclinical program for the diabetes project. BioStock was able to reach CEO Jan Alenfall on All Saints’ Day weekend for further comments on the capital raise and what it means for the company.Read the full interview with Follicum's CEO Jan Alenfall at biostock.se: https://www.biostock.se/en/follicums-ceo-comments-on-directed-share-issue-of-sek-37-million/

Follicum carries out a directed share issue of approximately SEK 36.6 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, BE SUBJECT TO LEGAL RESTRICTIONS OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES.The board of directors of Follicum AB (“Follicum” or the “Company”) has, pursuant to the authorisation granted by the annual general meeting on 4 June 2020, resolved on a directed issue of approximately SEK 36.6

Follicum obtains patent in the United States for the company's peptides for the treatment of diabetes and related complications

Follicum AB  announced today that the patent which previously (June 22, 2020) received a so-called Notice of Allowance from the US Patent and Trademark Office ("USPTO") has now also been formally approved by the authority. The patent is called "Peptides for Treatment of Diabetes" and the patent will be valid until 2038.The patent (US 10815283) covers peptides from the company's two peptide classes and their use in the treatment of diabetes and its complications. The patent will be formally approved on October 27, 2020. CEO Jan Alenfall comments: "The US is by far the largest market

BioStock: Follicum finalises patient recruitment in hair growth study

Alopecia patients have very few treatment options available to them. Those that exist are often ineffective and come with a multitude of side effects, and they mainly target men. Follicum’s FOL-005 is a compound in clinical development that has the potential not only to compete against current hair-loss medications in terms of efficacy, but it could potentially treat women as well as it could men. The Swedish biotech company recently announced it has completed patient recruitment for its phase II study and look forward to presenting data in the first half of 2021.Read the full article at

All patients included in Follicum's Phase II study with FOL-005 for stimulation of hair growth

Follicum AB today announced that all patients have been included in the company's ongoing Phase IIa clinical study with its lead drug candidate FOL-005. The study involves more than 200 male patients with hair loss who are being treated with a newly developed topical formulation of FOL-005. No noteworthy adverse reactions have been reported so far and to date none of the patients included have discontinued their participation in the study. The results are expected to be presented in spring 2021.The ongoing double-blind and placebo-controlled Phase II study examines the safety and efficacy

BioStock: Follicum reaches milestone in hair study

Yesterday, Follicum announced that they have recruited over 50 per cent of the intended patient group for their ongoing phase IIa trial with the topical formulation of the hair growth stimulating candidate FOL-005. Thus, the study is well on its way to keeping the communicated timelines, and results are expected in the spring.Read the full article at biostock.se: https://www.biostock.se/en/follicum-reaches-milestone-in-hair-study/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

More than 50% of patients enrolled in Follicum's Phase II study of FOL-005 for stimulation of hair growth

Follicum AB ("Follicum" or the "company") today announced that more than 50% of the patients have  been recruited in the ongoing, clinical phase IIa study with FOL-005. The study involves 200 male patients with hair loss who are treated daily for four months with a newly developed topical formulation of FOL-005 or placebo. The study is being conducted at the Clinical Research Center for Hair and Skin Science ("CRC") in Berlin, at proDERM in Hamburg and at CentroDerm® in Wuppertal.Two previous clinical studies have shown that intradermal injections of FOL-005 are an effective and safe

BioStock: New patent notice rounds off an eventful six months for Follicum

During the first half of 2020, Follicum has started, paused and resumed a phase II study with its primary candidate FOL-005. An international patent application has been filed regarding its newly developed topical formulation as a carrier of peptide drugs. New collaborations have been entered in regard to the company’s diabetes project and several patents have been obtained, most recently from the US Patent Office. As of now, the company has a solid IP protection for its peptides developed with the aim of treating diabetes and its complications, in both Europe and the United States, and the

Follicum AB receives Notice of Allowance from the US Patent Office for the protection of the company's peptides developed for the treatment of diabetes and its related complications

Follicum AB ("Follicum") has received information that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance of the US patent application 16/666,960. The patent application covers the company's peptides and their use for treatment of diabetes and diabetes-associated complications.The application is directed to new peptides from the company's two peptide classes, and their use in the treatment of diabetes and its complications. Follicum has now received Notice of Allowance for this application. In short, a Notice of Allowance means that the patent office in

BioStock: Follicum represents R&D at MVA’s diabetes webinar

Tomorrow, world-leading diabetes experts and front runners of regional R&D in type 1 diabetes will gather at a free Medicon Valley Alliance webinar. Lund-based Follicum will be among the participants, and BioStock has talked to CEO Jan Alenfall regarding the webinar and the company’s diabetes project.Read the full interview at biostock.se: https://www.biostock.se/en/follicum-represents-rd-at-mvas-diabetes-webinar/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Follicum re-starts phase II study with FOL-005 for stimulation of hair growth and expands the number of study centres

Follicum AB ("Follicum" or the "company") today announced that the clinical Phase IIa study with a cream-like formulation of  FOL-005 will re-start, following a pause due to the Covid-19 pandemic. To increase the recruitment rate, a third study centre has been contracted. The study comprises approximately 200 male patients with hair loss who are treated daily for four months with the newly developed formulation of FOL-005 or placebo. The study is being conducted at the Clinical Research Center for Hair and Skin Science ("CRC") in Berlin, proDERM in Hamburg, and the new center, CentroDerm® in

There are no items matching the current filter
There are no more items matching the current filter
Back to top